RNP Therapeutics

RNP Therapeutics is engaging non-coding RNA (ncRNA) to target the components of tumor microenvironment (TME). TME is a battle ground between tumor and host immune system. To date, RNP Therapeutics has developed a platform for targeting the component of TME through modulating non-coding RNA, such as microRNA, 3' UTR and lncRNA. We have identified promising drug candidate to improve tumor response to PD1/PD-L1 checkpoint therapy